Avanos Medical (NYSE: AVNS) furnishes JP Morgan Healthcare Conference presentation
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Avanos Medical, Inc. filed a current report describing an investor presentation being given at the JP Morgan Healthcare Conference. On January 13, 2026, the company will present and discuss a slide deck that is included as Exhibit 99.1 to this report and incorporated by reference for informational purposes.
The company clarifies that the materials furnished under Regulation FD are not considered “filed” under the Securities Exchange Act and are not subject to related liability provisions. These materials will also not be automatically incorporated into any securities registration statements or other documents unless specifically stated in those future filings.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: January 13, 2026
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission file number) | (I.R.S. Employer Identification No.) | ||||||||||||||||||
| (Address of principal executive offices) | (Zip code) | |||||||||||||||||||
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On January 13, 2026, Avanos Medical, Inc. will present and discuss during the JP Morgan Healthcare Conference the slide presentation furnished herewith as Exhibit 99.1 to this Current Report and incorporated herein by reference.
The information furnished pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
| Exhibit No. | Description | |||||||
99.1 | Presentation dated January 13, 2026 delivered to JP Morgan Healthcare Conference | |||||||
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVANOS MEDICAL, INC. | ||||||||||||||
| Date: | January 13, 2026 | By: | /s/ John J. Hurley | |||||||||||
| John J. Hurley Controller | ||||||||||||||
FAQ
What did Avanos Medical (AVNS) disclose in this 8-K filing?
Avanos Medical disclosed that it will present and discuss a slide presentation at the JP Morgan Healthcare Conference on January 13, 2026, and furnished that presentation as Exhibit 99.1.
What is Exhibit 99.1 in Avanos Medical's 8-K for AVNS?
Exhibit 99.1 is a slide presentation dated January 13, 2026 that Avanos Medical is using for its JP Morgan Healthcare Conference appearance.
Is the Avanos Medical JP Morgan Conference presentation considered "filed" with the SEC?
No. The company states that the information furnished under Item 7.01, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Will the Avanos Medical (AVNS) presentation be incorporated into future registration statements?
The company states that the Item 7.01 information, including Exhibit 99.1, will not be incorporated by reference into registration statements or other documents unless expressly stated in those future filings.
Which SEC item does Avanos Medical use to disclose the JP Morgan presentation?
Avanos Medical uses Item 7.01, Regulation FD Disclosure, to furnish the JP Morgan Healthcare Conference presentation.
Who signed this Avanos Medical (AVNS) 8-K report?
The report was signed on behalf of Avanos Medical, Inc. by John J. Hurley, Controller, on January 13, 2026.